NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/10/2024
Back to search
Official data from USPTO
COPAXONE 40MG/ML (GLATIRAMER ACETATE INJECTION) THREE TIMES A WEEK RX ONLY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
10/10/2024
Trademark type
Combined
Nice classes
5
Filing date
10/16/2017
Registration date
08/07/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/10/2024
Last transaction
10/10/2024
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
01/28/2014
First use in commerce
01/28/2014
Drawing code
3
Owner type
99
Owner location
Petach Tikva, IL
Examiner
ALVAREZ, COURTNEY
Current location
Historical data usage
Mark description
The mark consists of a gray band that comes to a point at the bottom right. Inside the band are the words "Rx Only" in small navy letters on the left side of the band. The words "three times a week" in capital navy blue letters to the right of "Rx Only". The word "COPAXONE" in capital navy blue letters to the right of "three times a week". The words "glatiramer acetate injection" in lower case navy blue letters in parenthesis underneath the word "COPAXONE". A gray triangle with a white outline is on the right of the band. Inside the triangle is "40 mg/mL" in navy blue.
Holders and representatives
Holders
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited
Representatives
Laurence Rickles TEVA PHARMACEUTICALS USA, INC.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparation for use in human medicine for the treatment of multiple sclerosis containing glatiramer acetate
Publications
History of USPTO decisions and trademark events.
30 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/10/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/10/2024
E815
TEAS SECTION 8 & 15 RECEIVED
04/11/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/07/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/22/2018
PUBO
PUBLISHED FOR OPPOSITION
05/22/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/02/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/18/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
04/18/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/18/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
04/18/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/18/2018
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/09/2018
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
03/20/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/06/2018
ALIE
ASSIGNED TO LIE
03/05/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/27/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/23/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/23/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/23/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/23/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/01/2018
GNRT
NON-FINAL ACTION E-MAILED
02/01/2018
CNRT
NON-FINAL ACTION WRITTEN
02/01/2018
DOCK
ASSIGNED TO EXAMINER
01/25/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/26/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/25/2017
NWAP
NEW APPLICATION ENTERED
10/19/2017
Continuous trademark protection
Get notified about every new filing that threatens COPAXONE 40MG/ML (GLATIRAMER ACETATE INJECTION) THREE TIMES A WEEK RX ONLY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.